Coeptis Therapeutics Leverages Artificial Intelligence and Blockchain for Next-Generation Innovation
Rhea-AI Summary
Coeptis Therapeutics Holdings (Nasdaq: COEP), a biopharmaceutical company specializing in cell therapy platforms, has announced the expansion of its technological initiatives to include artificial intelligence and blockchain solutions. Following the successful launch of its Technology Division, the company aims to enhance operational efficiency and customer engagement through these advanced technologies.
CEO Dave Mehalick expressed enthusiasm about building upon the momentum generated by their Technology Division, particularly in AI, while exploring blockchain opportunities. The company views this expansion as a strategic move to remain at the forefront of technological developments and adapt to the evolving digital marketplace.
Positive
- Successfully launched Technology Division with AI capabilities
- Strategic expansion into blockchain technology
Negative
- None.
Coeptis Harnesses AI Advances and Blockchain Initiatives to Drive Operational Efficiency and Strategic Growth
Following the successful launch of its Technology Division and the introduction of transformative AI capabilities, Coeptis has demonstrated significant promise in enhancing operational efficiency and customer engagement. The Company recognizes the enormous potential for AI to revolutionize the pharmaceutical landscape while exploring the opportunities provided by blockchain technology.
Dave Mehalick, President and CEO of Coeptis, stated, "We are thrilled to build upon the momentum we've generated with our Technology Division, particularly in the area of artificial intelligence, as we look to advance our initiatives leveraging blockchain technology. This expansion signifies not only our commitment to remaining at the forefront of technological developments but also our dedication to exploring new avenues that align with the rapidly evolving digital marketplace."
"The integration of blockchain initiatives into the Technology Division's portfolio reflects Coeptis's mission to adapt to emerging trends and leverage new market opportunities for enhanced value creation," added Mr. Mehalick. As we embark on this new journey, we are confident in our ability to drive innovation and explore synergies that will benefit our customers and shareholders.
About Coeptis Therapeutics Holdings, Inc.
Coeptis Therapeutics Holdings, Inc., together with its subsidiaries including Coeptis Therapeutics, Inc., Coeptis Pharmaceuticals, Inc., GEAR Therapeutics, Inc., and SNAP Biosciences, Inc. (collectively "Coeptis"), is a biopharmaceutical and technology company focused on developing innovative cell therapy platforms for cancer, autoimmune, and infectious diseases. Coeptis aims to advance treatment paradigms and improve patient outcomes through its cutting-edge research and development efforts.
The Company's therapeutic portfolio is underscored by assets licensed from Deverra Therapeutics, which include an allogeneic cellular immunotherapy platform and DVX201, a clinical-stage, unmodified natural killer cell therapy technology. Coeptis is also developing a universal, multi-antigen CAR technology licensed from the University of
Building on its core competencies, Coeptis has recently established a Technology Division, which focuses on enhancing operational capabilities through advanced technologies. This division features AI-powered marketing software and robotic process automation tools acquired from NexGenAI Solutions Group, designed to optimize business processes and improve overall efficiency.
Headquartered in
Cautionary Note Regarding Forward-Looking Statements
This press release and statements of our management made in connection therewith contain or may contain "forward-looking statements" (as defined in Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended). Forward-looking statements include statements concerning our plans, objectives, goals, strategies, future events or performance, and underlying assumptions, and other statements that are other than statements of historical facts. When we use words such as "may," "will," "intend," "should," "believe," "expect," "anticipate," "project," "estimate" or similar expressions that do not relate solely to historical matters, we are making forward-looking statements. Forward-looking statements are not a guarantee of future performance and involve significant risks and uncertainties that may cause the actual results to differ materially and perhaps substantially from our expectations discussed in the forward-looking statements. Factors that may cause such differences include but are not limited to: (1) the inability to maintain the listing of the Company's securities on the Nasdaq Capital Market; (2) the inability to recognize the anticipated benefits of the Deverra licensed assets, which may be affected by, among other things, competition, the ability of the Company to grow and manage growth economically and hire and retain key employees; (3) the risks that the Company's products in development or the newly-licensed assets fail clinical trials or are not approved by the
Contacts
View original content to download multimedia:https://www.prnewswire.com/news-releases/coeptis-therapeutics-leverages-artificial-intelligence-and-blockchain-for-next-generation-innovation-302358118.html
SOURCE Coeptis Pharmaceuticals, Inc.
FAQ
What new technologies is Coeptis Therapeutics (COEP) implementing in 2025?
How is Coeptis Therapeutics (COEP) leveraging AI in its operations?
What is the purpose of Coeptis Therapeutics' (COEP) blockchain initiative?
When did Coeptis Therapeutics (COEP) announce its AI and blockchain expansion?
